-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professional reading reference only
Come and learn!
Screenshots of guidelines published
Scan the QR code above to get more information on cancer guidelines
DS8201
Can be used for HER2 low expression/positive metastatic breast cancer
The guideline update recommends that DS8201 should be used in patients with HER2 IHC 1+/IHC 2+ and ISH-negative metastatic breast cancer who have received at least first-line chemotherapy for metastatic disease, and those who are hormone receptor-positive and refractory to endocrine therapy (based on Evidence-based evidence, benefits outweigh harms; quality of evidence: moderate; strength of recommendation: strong recommendation)
The recommended evidence for DS8201 in the guideline is based on DESTINY- Breast04 , a phase III, two-group, open-label, randomized, multicenter clinical trial:
Figure 1A
Figure 1C
Figure 1B
Figure 1D
Figure 2-1
Figure 2-2
Figure 2-3
